Becton Dickinson and Company (BDX) : The money flow analysis of Becton Dickinson and Company (BDX) indicates a $20.36 million of outflow was on downticks, whereas, the investors on Monday gobbled up stocks worth $27.27 million on upticks. The ratio between the upticks and downticks was clearly in favor of the bulls at 1.34 and so was the total money flow at $6.91 million. The bulls lapped up $9.36 million worth of block trades on upticks. The money flow was $9.36 million in block trades, underlining the interest of the bulls in the stock even when the stock was declining.However, the price action shows that the bears had an upper hand in the stock of Becton Dickinson and Company (BDX), pushing it down by -1.54% for the day. The stock slid $2.73 and traded at $173.98 during the day. Nonetheless, the stock is 0.14% over the previous weeks close.
Shares of Becton, Dickinson and Company appreciated by 0.4% during the last five trading days but lost 0.5% on a 4-week basis. Becton, Dickinson and Company is up 3.75% in the last 3-month period. Year-to-Date the stock performance stands at 14%.
Becton Dickinson and Company (NYSE:BDX): During Mondays trading session, Bulls were in full control of the stock right from the opening. The stock opened at $174.32 and $173.91 proved to be the low of the day. Continuous buying at higher levels pushed the stock towards an intraday high of $175.29. The buying momentum continued till the end and the stock did not give up its gains. It closed at $174.21, notching a gain of 0.13% for the day. The total traded volume was 526,567 . The stock had closed at $173.98 on the previous day.
In a related news, Cohen Gary M, officer (Executive Vice President) of Becton Dickinson & Co, unloaded 29,367 shares at an average price of $176.81 on August 11, 2016. The total amount of the transaction was worth $5,192,379, according to the disclosed information with the Securities and Exchange Commission in a Form 4 filing.
Becton, Dickinson and Company is a global medical technology company engaged in the development, manufacture and sale of a range of medical supplies, devices, laboratory equipment and diagnostic products used by healthcare institutions, life science researchers, clinical laboratories, pharmaceutical industry and the general public. The Company operates through two segments: BD Medical and BD Life Sciences. The Companys Life Sciences segment consists of the BD Diagnostics and BD Biosciences segments. The Companys BD Medical segment focuses on providing solutions to reduce the spread of infection, enhance diabetes treatment and advance drug delivery. The Companys BD Diagnostics provides products for the safe collection and transport of diagnostics specimens, as well as instruments and reagent systems. Its BD Biosciences provide diagnostic and research tools to life science researchers, clinical researchers, laboratory professionals and clinicians.